Phospholipase A2 is involved in muscarinic receptor-mediated sAPPalpha release independently of cyclooxygenase or lypoxygenase activity in SH-SY5Y cells.
The release of soluble amyloid precursor protein alpha (sAPPalpha), produced during alpha-secretase processing by cleavage within the beta amyloid peptide domain of APP, is highly regulated by several external and internal signals. Because evidence suggests the involvement of inflammatory processes in the pathology of Alzheimer's disease and APP formation, we examined the involvement of the phospholipase A2 (PLA2) pathway and of its downstream cyclooxygenase (COX) and lipoxygenase (LOX) pathways in the regulation of sAPPalpha, release induced by muscarinic receptor activation in SH-SY5Y cells. The amount of sAPP released into the culture medium was analyzed using a monoclonal 6E10 antibody detecting sAPPalpha. Treatment with the PLA2 inhibitor, manoalide, blocked the release of oxoM (muscarinic receptor agonist)-stimulated sAPPalpha, and the muscarinic receptor-mediated sAPPalpha release was increased by the non-selective PLA2 activator mellitin. COX and LOX inhibitors inhibited exogenous AA-induced sAPPalpha release, but upregulated basal constitutive sAPPalpha release. However, treatment with COX or LOX inhibitors failed to significantly change oxoM-stimulated sAPPalpha release, and furthermore, muscarinic receptor activation inhibited AA-stimulated COX activity. Our results suggest that sAPPalpha release induced by muscarinic receptor activation is regulated by AA generation via PLA2 activation independently of COX and LOX activities, but that the COX and LOX pathways are possibly involved in the constitutive release of sAPPalpha.
Cho
Hye-Won
HW
Research Institute of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, 11-1, Daehyun-Dong, Seodaemun-Gu, Seoul 120-750, Republic of Korea.
Kim
Jin Hyoung
JH
Choi
Shinkyu
S
Kim
Hwa-Jung
HJ
D016564:Amyloid beta-Protein Precursor / Q000378:metabolism*; D045744:Cell Line, Tumor; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D006801:Humans; D008084:Lipoxygenase / Q000378:metabolism*; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000502:physiology*; D054467:Phospholipases A2; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism*; D043643:Receptor, Muscarinic M1 / Q000502:physiology*; D043587:Receptor, Muscarinic M3 / Q000502:physiology*; D012995:Solubility
C489697:APLP1 protein, human; D016564:Amyloid beta-Protein Precursor; D016861:Cyclooxygenase Inhibitors; D016859:Lipoxygenase Inhibitors; D043643:Receptor, Muscarinic M1; D043587:Receptor, Muscarinic M3; D008084:Lipoxygenase; D011451:Prostaglandin-Endoperoxide Synthases; D010741:Phospholipases A; D054467:Phospholipases A2